Detalhe da pesquisa
1.
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol
; 167(3): 436-443, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36220670
2.
The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene.
Haematologica
; 106(2): 474-482, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107331
3.
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Int J Gynecol Cancer
; 31(10): 1369-1373, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607820
4.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
; 42(13): 1488-1498, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315944
5.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Target Oncol
; 16(1): 59-68, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369704